Study shows cheap drug could alleviate treatment-resistance in leukaemia 20 January 2020 | By Rachael Harper (Drug Target Review) A clinical study is to be launched after researchers found that a common and inexpensive drug may be used to counteract treatment resistance in patients with AML.
Researchers discover potential diet drug strategy without feeling of nausea 20 January 2020 | By Victoria Rees (Drug Target Review) A study has revealed a brain circuit in mice that suppresses the need to eat without a feeling of nausea, presenting a new strategy for diet drugs.
Metal-based fragment molecule library to screen for drug candidates 20 January 2020 | By Victoria Rees (Drug Target Review) Researchers have developed a novel metal-based fragment library of molecules that can be used to screen for new drug candidates.
New capillary model could provide new therapies for malaria 17 January 2020 | By Hannah Balfour (Drug Target Review) Researchers have produced a capillary model which allows investigation of the dynamics of blood flow obstruction in real scale and could be used to test new therapies for P. falciparum malaria.
Researchers discover α-synuclein clue to treating Parkinson’s 17 January 2020 | By Victoria Rees (Drug Target Review) A study has shown that fruit fly larvae lacking a certain region of the α-synuclein protein did not exhibit Parkinson’s symptoms, indicating a potential target.
MLL gene key to producing hematopoietic stem cells, says research 17 January 2020 | By Hannah Balfour (Drug Target Review) Researchers investigating childhood leukaemia have discovered that increasing MLL gene expression in iPSCs drives hematopoietic stem cell production, so could be the target of new therapies.
Researchers find VISTA molecule silences immune system against cancer 17 January 2020 | By Hannah Balfour (Drug Target Review) A new study shows that the VISTA molecule stops the immune system responding to self-antigens, including those presented by cancer cells, so an anti-VISTA antibody could be a possible therapy.
Industry collaborate to screen existing drugs to repurpose for cystic fibrosis 17 January 2020 | By Drug Target Review In an effort to address some of the more serious untreatable infections encountered by patients with cystic fibrosis, Calibr will collaborate with the Cystic Fibrosis Foundation on a two-year project.
Endometriosis symptoms in mice improved by cannabinoids 16 January 2020 | By Rachael Harper (Drug Target Review) A new study in mice has suggested that cannabinoids can relieve pain caused by endometriosis and paves the way for further clinical research.
DIRC3 tumour suppressor could be a new target for melanoma therapies 16 January 2020 | By Hannah Balfour (Drug Target Review) A study has shown that long non-coding RNA called DIRC3 can block melanoma growth and could be used to identify new targets for skin cancer therapies.
Novel small molecule could treat Alzheimer’s disease and Dravet syndrome 16 January 2020 | By Hannah Balfour (Drug Target Review) A new experimental drug was shown by researchers to restore natural brain rhythms in mouse models of Alzheimer’s and promote learning and memory.
Novel astrocyte target identified to treat drug addiction 16 January 2020 | By Victoria Rees (Drug Target Review) Researchers have revealed that astrocytes contribute to reward signalling in the brains of mice, so could be a novel target to treat drug addiction.
Novel form of cell-free therapy revealed by researchers 16 January 2020 | By Victoria Rees (Drug Target Review) Researchers have developed cytochalasin B-induced membrane vesicles which they suggest could be a new form of cell-free therapy in regenerative medicine.
Genes associated with heavy alcohol use may also impact compulsive behaviour and addiction 15 January 2020 | By Hannah Balfour (Drug Target Review) A study suggests there may be common genetic pathways between alcohol use disorder and other addictions, so GWAS identification of affected genes could provide the targets for new therapies.
Scientists find leukaemia’s Achilles heel in vitamin B6 15 January 2020 | By Mandy Parrett (Drug Target Review) A possible new avenue for treatment of Acute Myeloid Leukaemia (AML) has opened up after US scientists pinpoint how the cancer spreads using excessive amounts of vitamin B6.
